Press Releases

Date Title and Summary View
Toggle Summary Aquinox Announces Closing of $75.4 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
VANCOUVER, British Columbia , Sept. 23, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced the closing of its
View HTML
Toggle Summary Aquinox Prices Public Offering of Common Stock
VANCOUVER, British Columbia , Sept. 19, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced the pricing of an
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Proposed Public Offering of Common Stock
VANCOUVER, British Columbia , Sept. 19, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today announced that it intends to
View HTML
Toggle Summary Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome
VANCOUVER, British Columbia , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that it has
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Second Quarter 2016 Financial Results
Conference call update today at 4:30PM ET
View HTML
Toggle Summary Aquinox Pharmaceuticals to Announce Second Quarter 2016 Financial Results
Conference call Thursday, August 4, 2016 at 4:30PM ET
View HTML
Toggle Summary Aquinox to Present at Canaccord Genuity 36th Annual Growth Conference
VANCOUVER, British Columbia , Aug. 01, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox to Present at Jefferies 2016 Healthcare Conference
VANCOUVER, British Columbia , June 01, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that Kamran Alam
View HTML
Toggle Summary Aquinox Announces Executive Appointments
VANCOUVER, British Columbia , May 25, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, is pleased to announce the
View HTML
Toggle Summary Aquinox to Present at 2016 Annual UBS Global Healthcare Conference
VANCOUVER, British Columbia , May 18, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main ,
View HTML